Azenta Reports $160.8M Net Loss, ($3.49) EPS in Q2, Revenue Up Just 1%
AZTA is trading near its 52-week low of $17.11 (12% above the low) on elevated volume (2.2× avg).
Summary
Azenta, Inc. reported second-quarter 2026 results with a significant net loss of $160.8 million and diluted loss per share of ($3.49), on revenue of $144.8 million, which represents a modest 1% increase year-over-year. This follows a previous news report on May 5th that indicated a significant GAAP operating loss for Q2, with this headline providing the specific net income and EPS figures from the 10-Q filing. The substantial net loss is highly material for a company of Azenta's size, indicating significant underperformance and likely to exert strong downward pressure on the stock. Gross margin pressure from rework, excess inventory, and declining Sanger volume contributed to the loss, alongside the classification of B Medical Systems as held-for-sale. Investors will be closely watching for management's detailed commentary on these factors and their plans for improving profitability.
At the time of this announcement, AZTA was trading at $19.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $855.4M. The 52-week trading range was $17.11 to $41.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.